All In Biotech

Drug Trial Radar · NCT05198804

A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer

A Phase 1/2 Dose-Escalation and Dose-Expansion Study of ZN-c3 in Combination With Niraparib and ZN-c3 Monotherapy in Subjects With Platinum-Resistant Ovarian Cancer

Last checked: Nov 19, 2026Latest source record: Mar 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

117

Actual

Start

Jan 27, 2022

Primary completion

Oct 15, 2025

Study completion Jan 19, 2026

Sponsor

Sponsor type
Industry
First posted
Jan 20, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2 study to evaluate the safety, clinical activity, pharmacokinetics (PK), and pharmacodynamics (PD) of ZN-c3 in combination with niraparib and of ZN-c3 Monotherapy in subjects with platinum-resistant ovarian cancer.

Conditions

  • Ovarian Cancer
  • Platinum-resistant Ovarian Cancer
  • Primary Peritoneal Carcinoma
  • Fallopian Tube Cancer

Interventions

  • AzenosertibDrug

    Azenosertib

  • NiraparibDrug

    Niraparib

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To investigate the safety and tolerability of ZN-c3 in combination with niraparib, including identification of the MTD and RP2DTime frame: 6 months
  2. To determine the safety and tolerability of ZN-c3 monotherapyTime frame: 12 months
  3. To investigate the antitumor activity of ZN-c3 monotherapyTime frame: 12 months

Locations

22 sites in 2 countries. Site status is shown where the registry gives one.

  • Arizona Oncology Associates (Wilmot HOPE) - USOR

    Tucson, Arizona

  • Rocky Mountain Cancer Centers

    Aurora, Colorado

  • University of Colorado

    Aurora, Colorado

  • Mount Sinai Comprehensive Cancer Center

    Miami Beach, Florida

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Spectrum Health System

    Grand Rapids, Michigan

  • Rutgers New Jersey Medical School

    Newark, New Jersey

  • Optimum Clinical Research Group- Women's Oncology

    Albuquerque, New Mexico

  • The Blavatnik Family - Chelsea Medical Center at Mount Sinai

    New York, New York

  • Willamette Valley Cancer Institute and Research Center

    Eugene, Oregon

  • Women and Infants Hospital of Rhode Island

    Providence, Rhode Island

  • Texas Oncology-Fort Worth Cancer Center

    Fort Worth, Texas

  • MD Anderson Cancer Center, Gynecologic Oncology Center

    Texas City, Texas

  • University of Virginia

    Charlottesville, Virginia

  • Virginia Cancer Specialists

    Fairfax, Virginia

  • Virginia Commonwealth University

    Richmond, Virginia

  • Centre Georges François Leclerc

    Dijon, France

  • Centre Oscar Lambret

    Lille, France

  • Centre Hospitalier Lyon Sud

    Saint-Genis-Laval, France

  • ICANS - Institut de cancérologie Strasbourg Europe

    Strasbourg, France

  • EDOG - Institut Claudius Regaud

    Toulouse, France

  • Institut Gustave Roussy

    Villejuif, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.